Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283638 | 0.78 | CHRM5 (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL15240168 | 0.78 | CHRM5 (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL26998904 | 0.73 | DAO (0.38) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL8117123 | 0.71 | CHRM2 (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL8120519 | 0.71 | CHRM2 (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL21962777 | 0.71 | CA2 (0.39) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL6956559 | 0.71 | HTR2C (0.46) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL16661514 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL8104746 | 0.70 | CHRM2 (0.39) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL9259177 | 0.70 | CHRM2 (0.39) | CHRM2CHRM5CHRM3CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | CHRM2 302/4885CHRM5 864/4885CHRM3 583/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CHRM2 1636/4885CHRM5 2488/4885CHRM3 1008/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | CHRM2 3953/4885CHRM5 4565/4885CHRM3 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.